Normal Karyotype AML testing
Note that from 7 December 2016, testing of FLT3 has been
suspended until further notice. Please contact the laboratory for
further testing details.
As many patients do not have a specific translocation to
facilitate MRD monitoring, we routinely monitor for NPM1 and
FLT3-ITDs on the diagnostic pre-treatment sample.
This is usually done on PB alone for FLT3-ITDs and both PB and
BM for NPM1.
Two separate samples are required for FLT3-ITD and NPM1
screening because the tests are carried out on DNA and RNA
Therefore to facilitate appropriate testing, 15ml EDTA PB is
required for FLT3-ITD testing and a separate 15ml PB plus 2-3ml
EDTA BM for NPM1 testing.